Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06819735 | NOT YET RECRUITING | Advanced Solid Tumors

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Sponsor:

Domain Therapeutics Australia Pty Ltd

Brief Summary:

This is a phase 1/2, dose-escalation and cohort-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advanced solid tumors.

Condition or disease

Advanced Solid Tumors

Intervention/treatment

DT-7012

Immune checkpoint inhibitor

Phase

PHASE1

PHASE2

Detailed Description:

This is a phase 1/2, first-in-human, multicenter, open-label clinical study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012, administered as monotherapy and in combination with an immune checkpoint inhibitor (ICI), in participants with selected recurrent advanced/metastatic solid tumors. This study includes: * a phase 1 Dose Escalation with two planned parts (part 1A which corresponds to a dose escalation of DT-7012 monotherapy and part 1B which will be initiated upon recommendation from the Safety Review Committee based on part 1A data and corresponds to a dose escalation of a combination of DT-7012 with an ICI) * a subsequent phase 2 Cohort Expansion The phase 1 aims at determining the recommended phase 2 dose (RP2D) and the maximum tolerated dose or maximum administered dose of DT-7012 as single agent and in combination with an ICI in participants with selected recurrent advanced/metastatic solid tumors. The phase 2 will assess DT-7012 as monotherapy and/or in combination with an ICI in expansion cohorts of 2-3 specific tumor types.

Study Type : INTERVENTIONAL
Estimated Enrollment : 60 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (DOMISOL, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)
Actual Study Start Date : 2025-06
Estimated Primary Completion Date : 2027-09
Estimated Study Completion Date : 2028-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Histologically or cytologically confirmed solid tumor, among selected cancer types, that is recurrent, locally advanced (i.e., not eligible for curative surgery or radiotherapy) or metastatic, has progressed after at least one line of systemic therapy and has no established curative option.
  • * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the local site investigator/radiologist.
  • * At least 1 tumour lesion accessible to biopsy per treating physician judgement.
  • * Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
  • * Adequate organ function.
Exclusion Criteria
  • * Any unresolved AEs from previous anti-cancer therapies of grade ≥2, with the exception of alopecia.
  • * Prior severe immune-related AEs (irAEs) leading to immunotherapy treatment discontinuation.
  • * Major surgery or significant traumatic injury within 4 weeks prior to Cycle 1 Day 1 with unadequately recovered AEs and/or complications from the intervention prior to Cycle 1 Day 1.
  • * Prior radiotherapy within the 4 weeks prior to Cycle 1 Day 1 or limited field palliative radiotherapy within 2 weeks prior to Cycle 1 Day 1.
  • * Prior anti-CCR8 monoclonal antibody treatment received in an investigational trial
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

Location Details

NCT06819735

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

No Location Found